Christopher Melani

Christopher Melani

National Cancer Institute - Bethesda / United States
Others
AD Scientific Index ID: 4393172
person_outline Christopher Melani's MOST POPULAR ARTICLES
1-) Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphomaMS Lionakis, K Dunleavy, M Roschewski, BC Widemann, JA Butman, ...Cancer cell 31 (6), 833-843. e5, 20173862017
2-) Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC …K Dunleavy, MA Fanale, JS Abramson, A Noy, PF Caimi, S Pittaluga, ...The Lancet Haematology 5 (12), e609-e617, 20181242018
3-) Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphomaM Roschewski, K Dunleavy, JS Abramson, BL Powell, BK Link, P Patel, ...Journal of Clinical Oncology 38 (22), 2519, 2020652020
4-) Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorderC Melani, ES Jaffe, WH WilsonBlood, The Journal of the American Society of Hematology 135 (16), 1344-1352, 2020962020
5-) End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision makingC Melani, R Advani, M Roschewski, KM Walters, CC Chen, L Baratto, ...Haematologica 103 (8), 1337, 2018822018